EA025531B1 - Диметилбензойные кислоты - Google Patents
Диметилбензойные кислоты Download PDFInfo
- Publication number
- EA025531B1 EA025531B1 EA201492140A EA201492140A EA025531B1 EA 025531 B1 EA025531 B1 EA 025531B1 EA 201492140 A EA201492140 A EA 201492140A EA 201492140 A EA201492140 A EA 201492140A EA 025531 B1 EA025531 B1 EA 025531B1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- scheme
- amino
- mmol
- methyl
- solution
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/42—Oxygen atoms attached in position 3 or 5
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Rheumatology (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261665956P | 2012-06-29 | 2012-06-29 | |
| US201361778969P | 2013-03-13 | 2013-03-13 | |
| PCT/US2013/046685 WO2014004230A1 (en) | 2012-06-29 | 2013-06-20 | Dimethyl-benzoic acid compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA201492140A1 EA201492140A1 (ru) | 2015-10-30 |
| EA025531B1 true EA025531B1 (ru) | 2017-01-30 |
Family
ID=48746667
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201492140A EA025531B1 (ru) | 2012-06-29 | 2013-06-20 | Диметилбензойные кислоты |
Country Status (40)
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110015221A1 (en) * | 2003-12-23 | 2011-01-20 | Pierre Fabre Medicament | Pharmaceutical composition of vinflunine which is intended for parenteral administration preparation method thereof and use of same |
| TWI572597B (zh) * | 2012-06-29 | 2017-03-01 | 美國禮來大藥廠 | 二甲基－苯甲酸化合物 |
| EP2765128A1 (en) * | 2013-02-07 | 2014-08-13 | Almirall, S.A. | Substituted benzamides with activity towards EP4 receptors |
| TWI636046B (zh) | 2013-05-17 | 2018-09-21 | 美國禮來大藥廠 | 苯氧基乙基二氫－１ｈ－異喹啉化合物 |
| JP6200596B2 (ja) | 2013-12-17 | 2017-09-20 | イーライ リリー アンド カンパニー | ジメチル安息香酸化合物 |
| US10189788B2 (en) | 2014-09-09 | 2019-01-29 | Bayer Pharma Aktiengesellschaft | Substituted N,2-diarylquinoline-4-carboxamides and the use thereof as anti-inflammatory agents |
| CR20180323A (es) | 2015-11-20 | 2018-08-06 | Idorsia Pharmaceuticals Ltd | Derivados de indol n-sustituídos como moduladores de los receptores de pge2 |
| PE20191616A1 (es) * | 2017-04-10 | 2019-11-05 | Bayer Ag | N-ariletil-2-arilquinolina-4-carboxamidas sustituidas y su uso |
| TWI770157B (zh) * | 2017-04-10 | 2022-07-11 | 德商拜耳廠股份有限公司 | 經取代之n-芳基乙基-2-胺基喹啉-4-甲醯胺及其用途 |
| PE20191787A1 (es) | 2017-05-18 | 2019-12-24 | Idorsia Pharmaceuticals Ltd | Derivados de indol n-sustituidos |
| KR102612140B1 (ko) | 2017-05-18 | 2023-12-08 | 이도르시아 파마슈티컬스 리미티드 | 피리미딘 유도체 |
| AR111808A1 (es) | 2017-05-18 | 2019-08-21 | Idorsia Pharmaceuticals Ltd | Derivados de pirimidina como moduladores del receptor de pge2 |
| EA201992676A1 (ru) | 2017-05-18 | 2020-05-06 | Идорсия Фармасьютиклз Лтд | Фенильные производные в качестве модуляторов pge2 рецепторов |
| US11325899B2 (en) | 2017-05-18 | 2022-05-10 | Idorsia Pharmaceuticals Ltd | Benzofurane and benzothiophene derivatives as PGE2 receptor modulators |
| JP7816164B2 (ja) | 2020-11-13 | 2026-02-18 | 小野薬品工業株式会社 | Ｅｐ４拮抗薬と免疫チェックポイント阻害物質との併用によるがん治療 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2000355551A (ja) * | 1999-06-15 | 2000-12-26 | Nikken Chem Co Ltd | 医薬組成物 |
| US7705035B2 (en) * | 2006-06-12 | 2010-04-27 | Merck Frosst Canada Ltd. | Indoline amide derivatives as EP4 receptor ligands |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1270615B (it) | 1994-07-14 | 1997-05-07 | Smithkline Beecham Farma | Uso di derivati di chinolina |
| MXPA06003123A (es) | 2003-09-22 | 2006-05-31 | Euro Celtique Sa | Agentes terapeuticos utiles para el tratamiento del dolor. |
| US7326732B2 (en) | 2004-02-12 | 2008-02-05 | Pharmagene Laboratories Limited | EP2 receptor agonists |
| KR20090122931A (ko) * | 2007-03-26 | 2009-12-01 | 아스테라스 세이야쿠 가부시키가이샤 | 오르니틴 유도체 |
| WO2012004293A2 (de) | 2010-07-08 | 2012-01-12 | Bayer Cropscience Ag | Insektizide und fungizide wirkstoffkombinationen |
| CA2831978A1 (en) | 2011-03-03 | 2012-09-07 | Universitat Des Saarlandes | Biaryl derivatives as selective 17beta-hydroxysteroid dehydrogenase type 2 inhibitors |
| TWI572597B (zh) * | 2012-06-29 | 2017-03-01 | 美國禮來大藥廠 | 二甲基－苯甲酸化合物 |
-
2013
- 2013-06-11 TW TW102120796A patent/TWI572597B/zh not_active IP Right Cessation
- 2013-06-13 AR ARP130102078 patent/AR091431A1/es unknown
- 2013-06-13 JO JOP/2013/0178A patent/JO3221B1/ar active
- 2013-06-20 SI SI201330576A patent/SI2867218T1/sl unknown
- 2013-06-20 MX MX2014015952A patent/MX347476B/es active IP Right Grant
- 2013-06-20 PL PL13734249T patent/PL2867218T3/pl unknown
- 2013-06-20 AP AP2014008165A patent/AP4063A/en active
- 2013-06-20 ES ES13734249.9T patent/ES2623099T3/es active Active
- 2013-06-20 SG SG11201408629QA patent/SG11201408629QA/en unknown
- 2013-06-20 EA EA201492140A patent/EA025531B1/ru not_active IP Right Cessation
- 2013-06-20 ME MEP-2017-83A patent/ME02655B/me unknown
- 2013-06-20 IN IN2356MUN2014 patent/IN2014MN02356A/en unknown
- 2013-06-20 PT PT137342499T patent/PT2867218T/pt unknown
- 2013-06-20 LT LTEP13734249.9T patent/LT2867218T/lt unknown
- 2013-06-20 PE PE2014002531A patent/PE20150185A1/es active IP Right Grant
- 2013-06-20 DK DK13734249.9T patent/DK2867218T3/en active
- 2013-06-20 NZ NZ701894A patent/NZ701894A/en not_active IP Right Cessation
- 2013-06-20 RS RS20170231A patent/RS55756B1/sr unknown
- 2013-06-20 US US13/922,277 patent/US8642768B2/en not_active Expired - Fee Related
- 2013-06-20 CA CA2875572A patent/CA2875572C/en not_active Expired - Fee Related
- 2013-06-20 HR HRP20170540TT patent/HRP20170540T1/hr unknown
- 2013-06-20 BR BR112014029551A patent/BR112014029551A2/pt not_active IP Right Cessation
- 2013-06-20 EP EP13734249.9A patent/EP2867218B1/en active Active
- 2013-06-20 KR KR1020147036136A patent/KR101634032B1/ko not_active Expired - Fee Related
- 2013-06-20 CN CN201380030138.XA patent/CN104334540B/zh not_active Expired - Fee Related
- 2013-06-20 MY MYPI2014703973A patent/MY172860A/en unknown
- 2013-06-20 AU AU2013280779A patent/AU2013280779B2/en not_active Ceased
- 2013-06-20 HU HUE13734249A patent/HUE032398T2/en unknown
- 2013-06-20 JP JP2015520305A patent/JP6114824B2/ja active Active
- 2013-06-20 WO PCT/US2013/046685 patent/WO2014004230A1/en not_active Ceased
- 2013-12-04 US US14/096,469 patent/US8933098B2/en not_active Expired - Fee Related
-
2014
- 2014-11-24 ZA ZA2014/08631A patent/ZA201408631B/en unknown
- 2014-11-28 TN TN2014000500A patent/TN2014000500A1/fr unknown
- 2014-12-03 CR CR20140554A patent/CR20140554A/es unknown
- 2014-12-11 IL IL236218A patent/IL236218A/en active IP Right Grant
- 2014-12-17 GT GT201400289A patent/GT201400289A/es unknown
- 2014-12-17 DO DO2014000286A patent/DOP2014000286A/es unknown
- 2014-12-18 CO CO14278424A patent/CO7160064A2/es unknown
- 2014-12-26 CL CL2014003537A patent/CL2014003537A1/es unknown
-
2015
- 2015-01-05 PH PH12015500008A patent/PH12015500008B1/en unknown
-
2017
- 2017-04-12 CY CY20171100435T patent/CY1118830T1/el unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2000355551A (ja) * | 1999-06-15 | 2000-12-26 | Nikken Chem Co Ltd | 医薬組成物 |
| US7705035B2 (en) * | 2006-06-12 | 2010-04-27 | Merck Frosst Canada Ltd. | Indoline amide derivatives as EP4 receptor ligands |
Non-Patent Citations (2)
| Title |
|---|
| CHEMICAL ABSTRACTS, 26 December 2000, Columbus, Ohio, US; KAWAHARA YOSHIKAZU, OHMORI HIROMASA: "Synergistic anti-inflammatory, antiallergy, and antiasthmatic agents for treatment of arachidonate metabolism disorders" XP002714917 * |
| COLUCCI, J. ; BOYD, M. ; BERTHELETTE, C. ; CHIASSON, J.F. ; WANG, Z. ; DUCHARME, Y. ; FRIESEN, R. ; WRONA, M. ; LEVESQUE, J.F. ; D: "Discovery of 4-{1-[({1-[4-(trifluoromethyl)benzyl]-1H-indol-7-yl}carbonyl)amino]cyclopropyl}benzoic acid (MF-766), a highly potent and selective EP"4 antagonist for treating inflammatory pain", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, AMSTERDAM, NL, vol. 20, no. 12, 15 June 2010 (2010-06-15), AMSTERDAM, NL, pages 3760 - 3763, XP027351247, ISSN: 0960-894X * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112969696B (zh) | 乙酰化书写器抑制剂的开发及其用途 | |
| JP6114824B2 (ja) | ジメチル安息香酸化合物 | |
| RU2479576C2 (ru) | Амидное соединение | |
| JP6200596B2 (ja) | ジメチル安息香酸化合物 | |
| RU2684906C2 (ru) | Амидные соединения | |
| JPWO2009005076A1 (ja) | アミド化合物 | |
| RU2658821C1 (ru) | Соль моноциклического производного пиридина и ее кристалл | |
| WO2016021742A1 (en) | Heterocyclic compounds as ep4 receptor antagonists | |
| JPWO2008123207A1 (ja) | オルニチン誘導体 | |
| CN111566102A (zh) | 作为激活素受体样激酶抑制剂的取代的吡咯并吡啶 | |
| CN103328442A (zh) | 可用于治疗代谢性和炎性疾病的氮杂环丁烷衍生物 | |
| TW201443004A (zh) | 苯氧基乙氧基化合物 | |
| JPWO2015146929A1 (ja) | 複素環化合物 | |
| WO2016088903A1 (en) | Heterocyclic compounds | |
| CN121794256A (zh) | 作为gpr183拮抗剂用于治疗慢性疼痛的2-苯氧基-1-(4-(烷基磺酰基)哌啶-1-基)乙-1-酮和3-苯基-1-(4-(烷基磺酰基)哌啶-1-基)丙-2-烯-1-酮衍生物 | |
| WO2015146928A1 (ja) | 複素環化合物 | |
| RU2854581C2 (ru) | Кристаллическая форма пиримидинсульфонамидного соединения и способ ее получения | |
| Bhole et al. | Effective potential studies for some new hybrid molecules for their activity against prostate cancer | |
| HK1203936B (en) | Dimethyl-benzoic acid compounds useful for the treatment of inflammatory conditions | |
| FR2949466A1 (fr) | Derives de 2-pyridin-2-yl-pyrazol-3(2h)-one, leur preparation et leur application en therapeutique comme activateurs de hif |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG TJ TM |
|
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): RU |